Alpharetta-based Clearside Biomedical Inc. also announced a Chinese company has obtained licensing for commercialization and development of its drug Xipere, to treat macular edema associated with uveitis, in greater China. It also announced license and collaboration revenue of $2.2 million in the year ended Dec. 31, 2019, compared to $30,000 for the year ended Dec. 31, 2018.
from Bizjournals.com Feed (2019-07-18 12:47:42) https://www.bizjournals.com/atlanta/news/2020/03/17/eye-disease-pharmaceutical-company-makes-change-at.html?ana=brss_609
Mold Remediation Pros
No comments:
Post a Comment